Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Paediatric therapeutic development workshop on medulloblastoma.

British journal of cancer·2026

Same author

From developmental origins to relapse: molecular and therapeutic insights in medulloblastoma.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery·2026

Same author

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

EClinicalMedicine·2026

Same author

BRAF Inhibition in Congenital Nevi and Neural Melanosis.

JAMA dermatology·2026

Same author

Tumor-derived cell-free DNA detected in cerebrospinal fluid enables minimally invasive profiling of pediatric brain tumors.

The Journal of clinical investigation·2026

Same author

Reirradiation for Patients With Recurrent Ependymoma Across the Age Spectrum.

Advances in radiation oncology·2026

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

Leading medulloblastoma to a differentiation end.

Carolina Nör¹, Vijay Ramaswamy²

¹Program in Developmental and Stem Cell Biology, Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada.

|August 13, 2024

Summary

Thyroid hormone treatment activates neurogenic differentiation factor 1 (NeuroD1) in medulloblastoma cells. This approach reverses EZH2 repression, promoting cell differentiation and offering a promising therapeutic strategy.

More Related Videos

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

Related Experiment Videos

Last Updated: Jul 13, 2026

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

Area of Science:

Oncology
Molecular Biology
Endocrinology

Background:

Medulloblastoma therapies currently lack efficacy and exhibit significant toxicity.
Developing less toxic and more effective treatments for medulloblastoma remains a critical challenge in pediatric oncology.

Purpose of the Study:

To investigate the therapeutic potential of thyroid hormone in medulloblastoma treatment.
To elucidate the molecular mechanisms underlying thyroid hormone-induced medulloblastoma cell differentiation.

Main Methods:

Treatment of medulloblastoma cells with thyroid hormone.
Analysis of neurogenic differentiation factor 1 (NeuroD1) activation.
Investigation of EZH2-mediated transcriptional repression of NeuroD1.

Main Results:

Thyroid hormone treatment successfully activated NeuroD1 expression in medulloblastoma cells.
This activation led to the differentiation of medulloblastoma cells.
The mechanism involved reversing EZH2-mediated transcriptional repression of NeuroD1.

Conclusions:

Thyroid hormone therapy represents a novel and less toxic approach for medulloblastoma.
Targeting EZH2-mediated repression of NeuroD1 is a viable strategy for inducing medulloblastoma cell differentiation.